New and updated preclinical and clinical data presented by biopharma firms at the European Society for Medical Oncology Virtual Congress 2020, including: Amgen, Astrazeneca, Bayer, Blueprint, BMS, Chi-Med, Eisai, Exelixis, Genentech, Genmab, Immunomedics, Innovent, Ipsen, Janssen, Lilly, Macrogenics, Merck, Novartis, Oncternal, Ose, Pieris, Regeneron, Roche, Sanofi, Seattle Genetics, Veru.

New and updated preclinical and clinical data to be presented by biopharma firms at the European Society for Medical Oncology Virtual Congress 2020, including: Agenus, Alkermes, Astrazeneca, Autolus, Ayala, Beigene, Daiichi, Deciphera, Eisai, Essa, Faron, Helsinn, Immunomedics, Immutep, Incyte, IO, Ipsen, Italfarmaco, Menarini, Mirati, Regeneron, Sanofi, Sensei, Spectrum, Sumitomo, Takeda.

New and updated preclinical and clinical data to be presented by biopharma firms at the European Society for Medical Oncology Virtual Congress 2020, including: ADC, Amunix, Bayer, Blueprint, BMS, Cardiff Oncology, Clovis, Corvus, Cullinan Pearl, Deciphera, Genentech, Genocea, Halozyme, Immunicum, Immunogen, Mersana, Noxxon, Oryzon, Roche, VBI.

HONG KONG – The use of artificial intelligence in drug discovery was back in the spotlight on the last day of the 2020 KoNECT-MOHW-MFDS International Conference, with drug developers pointing out both challenges and possible solutions.

HONG KONG – The Korean 2020 KoNECT-MOHW-MFDS International Conference, which is taking place online this year due to the COVID-19 pandemic, faced a challenging start. Technical difficulties hampered some of the early proceeding. However, technology took focus again later in the day in a more positive, with an exploration of artificial intelligence (AI).

New and updated preclinical and clinical data presented by biopharma firms at the European Society of Cardiology Congress 2020, including: Akcea, Amarin, Amgen, Arrowhead, Astrazeneca, Boehringer, Innovent, Lilly, Myokardia, Novartis.

While the COVID-19 pandemic has brought disruptions to R&D, market activities in the biopharmaceutical sector have remained active during the first half of this year in China. Venture capital investments, IPOs and partnering activity showed upward trends, except for M&A activity, which has declined for two years.